NAFDAC has issued Public Alert No. 024/2026 warning healthcare providers, pharmacists, and the general public about the circulation of counterfeit Augmentin 625mg Tablets in Nigeria.
The alert, released on Friday, May 15, 2026, targets the falsified product with the Batch No. AC3N (2 x 7 tablets pack). The agency received information from the Marketing Authorisation Holder for GlaxoSmithKline (GSK) products in Nigeria regarding suspected counterfeit versions of the popular antibiotic.
Public Alert No. 024/2026.
Alert on counterfeit Augmentin 625mg Tablets (Batch No. AC3N) in Nigeria#NAFDACAlertshttps://t.co/I39qv1MGe9— NAFDAC NIGERIA (@NafdacAgency) May 15, 2026
Augmentin (amoxicillin/clavulanic acid) is a widely used antibiotic for treating various bacterial infections. Counterfeit versions may contain incorrect amounts of active ingredients, no active ingredients at all, or harmful substances, which can lead to treatment failure, antibiotic resistance, or severe health complications.
GSK investigated the suspected products after receiving complaints and confirmed they were counterfeit based on documentary evidence, photographs, and social media videos. Although the batch number matches authentic stock previously supplied to Nigeria, significant discrepancies were discovered. The genuine Batch AC3N was manufactured in Worthing, United Kingdom, on August 23, 2023, and packed between September 19 and 20, 2023. However, the counterfeit samples show inconsistent manufacturing and expiry dates (Manufactured: September 2025 / Expiry: September 2028). Packaging discrepancies, including textual errors and poor fin seal quality, were also identified.
NAFDAC emphasised that no batch with the number AC3N was produced in September 2025, confirming the product as falsified.
Healthcare professionals and pharmacy operators are advised to immediately review their stock, quarantine any suspected counterfeit Augmentin 625mg Tablets (Batch No. AC3N), and discontinue sale or distribution of the affected batch. Members of the public who have purchased the product are urged to check the batch number and manufacturing/expiry dates carefully. Anyone in possession of the suspected counterfeit should stop using it and report it immediately.“
Report any suspected falsified or compromised products (medicines or medical devices) to the nearest NAFDAC office, call 0800-162-3322, or send an email to sf.alert@nafdac.gov.ng.”
This alert comes amid persistent public concerns about the proliferation of substandard and falsified medicines in Nigeria. Many citizens have called for stronger enforcement and better public communication. The incident also highlights the need for heightened vigilance when purchasing medicines from pharmacies and patent medicine stores across the country.
NAFDAC reaffirmed its commitment to protecting public health by removing falsified medicines from circulation and urged stakeholders to remain vigilant. As the agency continues investigations into how the counterfeit batch entered the market, Nigerians are encouraged to always verify the authenticity of medicines and report suspicious products promptly.
